STAT4 is a transcriptional regulator primarily expressed in hematopoietic cells that orchestrates immune responses through cytokine signaling 1. Upon IL-12 binding to its receptor IL-12RB2, STAT4 becomes tyrosine phosphorylated, homodimerizes, and translocates to the nucleus where it activates target genes 2. STAT4 can also be activated by IFN-gamma via JAK1/TYK2 and by other interleukins including IL-23 and IL-2 1. A critical function involves driving Th1 cell differentiation and interferon-gamma production, while also regulating T follicular regulatory cell development and innate lymphoid cell effector responses 2, 3. STAT4 gene polymorphisms substantially influence immune responses and disease susceptibility, with certain variants associated with altered expression/activity affecting cancer and autoimmune disease outcomes 4. Dysregulation of STAT4 occurs in multiple pathologies: autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis), cancers (with KRAS-mutant colorectal cancer showing sex-specific differences via STAT4-mediated KDM5D upregulation), and infectious diseases including tuberculosis and SARS-CoV-2 5, 6, 1. In glioblastoma, MET-driven STAT4 activation promotes PD-L1 expression and macrophage-mediated immunosuppression 7. These findings highlight STAT4's pivotal role in immune homeostasis and its therapeutic potential as a target in immune-related diseases.